Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers.
Saved in:
| Title: | Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers. |
|---|---|
| Authors: | Barber-Rotenberg JS; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Haas AR; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Aggarwal C; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., O'Hara M; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Hexner E; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Pequignot E; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Dowd E; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Ndeupen S; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Thai E; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Chen F; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Oner BS; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Czuczman C; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Gonzalez VE; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Fraietta JA; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA., Hwang WT; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA., Chew A; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Jadlowsky JK; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Marshall A; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Shea KM; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Jiang Y; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Cosey A; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Ferthio R; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Levine BL; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA., Plesa G; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA., Siegel DL; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA., Young RM; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA., Sheppard NC; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA., Albelda SM; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., June CH; Center for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA., Tanyi JL; Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: janos.tanyi@pennmedicine.upenn.edu. |
| Source: | Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2026 May 06; Vol. 34 (5), pp. 2653-2665. Date of Electronic Publication: 2026 Jan 21. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
